fluorofenidone

Fluorofenidone (AKF-PD) is a novel pyridone small molecule with demonstrated anti-fibrotic and anti-inflammatory properties. It has shown efficacy in experimental models of hepatic, renal, and pulmonary fibrosis by inhibiting key inflammatory and fibrotic pathways. The drug is currently under clinical investigation in China for liver fibrosis and chronic hepatitis B[2][4][6]. Its mechanisms include inhibition of TGF-β1 (Transforming growth factor beta 1), p38γ MAPK (p38 gamma mitogen-activated protein kinase), NF-κB signaling pathway, NADPH oxidase via the PI3K/Akt pathway, NALP3 inflammasome activation, IL-17 pathway modulation, and MKK4/JNK signaling[2][5][6]. Fluorofenidone also attenuates extracellular matrix deposition and reduces proinflammatory cytokine release.

Brand names

flufenidone

Other names

1-[3-fluorophenyl]-5-methyl-2-(1H)-pyridone1-(3-fluorophenyl)-5-methyl-2-(1H)-pyridone